[
  {
    "ts": "2025-11-11T02:16:37+00:00",
    "headline": "The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress",
    "summary": "Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA nephropathy and primary membranous nephropathy, alongside a favorable safety profile and regulatory designations from the FDA. This positions Vertex as the only company advancing a dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases, highlighting its growing presence in...",
    "url": "https://finance.yahoo.com/news/bull-case-vertex-pharmaceuticals-vrtx-021637539.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3f5c6c08-b454-396a-950a-6824973e368e",
      "content": {
        "id": "3f5c6c08-b454-396a-950a-6824973e368e",
        "contentType": "STORY",
        "title": "The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress",
        "description": "",
        "summary": "Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA nephropathy and primary membranous nephropathy, alongside a favorable safety profile and regulatory designations from the FDA. This positions Vertex as the only company advancing a dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases, highlighting its growing presence in...",
        "pubDate": "2025-11-11T02:16:37Z",
        "displayTime": "2025-11-11T02:16:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-vertex-pharmaceuticals-vrtx-021637539.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-vertex-pharmaceuticals-vrtx-021637539.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]